Pharma Journalist -

Curium and Lantheus have announced a definitive agreement to combine their businesses in a deal valued at up to approximately $8 billion, creating one of the world's largest…
Read More...

Ratio Therapeutics has secured $70 million in Series C financing to accelerate the development of its radiopharmaceutical pipeline, advance clinical trials, and expand its manufacturing…
Read More...

IMPACT Therapeutics has signed an exclusive licensing agreement with global specialty pharmaceutical company Pharmanovia to expand the reach of its ovarian cancer treatment, senaparib,…
Read More...

The European Commission has approved Datroway (datopotamab deruxtecan) as a first-line treatment for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are…
Read More...

miRecule has entered into a strategic research collaboration with Rio Biofarma Brasil Ltda. (RBBL), part of Brazilian pharmaceutical company EMS S.A., to develop peptide-mediated…
Read More...

Pfizer has reported positive topline results from two Phase 3 trials evaluating LITFULO (ritlecitinib) in patients with nonsegmental vitiligo (NSV), supporting the company’s plans to…
Read More...

Resilience has expanded its strategic manufacturing partnership with Eli Lilly and Company through a combined $750 million investment aimed at increasing US production of critical…
Read More...

AbCellera and Vertex Pharmaceuticals have entered into a collaboration to research, develop, manufacture and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases…
Read More...

EVERSANA has been selected by Tokyo-based biotechnology company Innovacell Inc. as its exclusive commercialization partner in the United States, a move aimed at supporting the…
Read More...

Taisho Pharmaceutical has secured exclusive rights to develop, register and commercialize Kaigene’s KG006, a next-generation FcRn inhibitor, in Japan under a new licensing agreement…
Read More...